Genetic Risk Scores Improve Prediction of Multiple Sclerosis Following Optic Neuritis
Optic neuritis (ON) is an inflammatory disorder of the optic nerve characterized by acute or subacute visual impairment, commonly affecting young adults. Although the condition itself is often treatable, its clinical significance lies in its association with systemic neuroinflammatory diseases—most notably multiple sclerosis (MS). Epidemiological studies indicate that approximately half of individuals who present with optic neuritis will ultimately receive a diagnosis of multiple sclerosis within 15 years. However, differentiating between optic neuritis associated with MS and non-MS etiologies at the time of initial presentation remains challenging. This diagnostic uncertainty has important therapeutic implications because treatment strategies differ substantially depending on the underlying cause.
The Role of Genetics in Multiple Sclerosis Risk
Multiple sclerosis is a complex autoimmune disease with both environmental and genetic determinants. Over the past decade, genome-wide association studies (GWAS) have identified numerous genetic variants associated with MS susceptibility. These discoveries have enabled the construction of polygenic or genetic risk scores (GRS), which integrate the cumulative effect of many risk alleles into a single quantitative metric. Genetic risk scores are increasingly used to estimate disease susceptibility and stratify patients according to their likelihood of developing specific conditions. In the context of optic neuritis, integrating genetic risk information may provide a valuable tool for identifying individuals who are more likely to transition to clinically diagnosed MS.
Study Design and Data Sources
To evaluate the predictive value of genetic risk scores for MS among patients presenting with optic neuritis, the investigators conducted a large-scale analysis using data from the UK Biobank. This population-based biomedical database includes genetic, demographic, and clinical information from hundreds of thousands of participants. The researchers developed a predictive model combining an MS genetic risk score with demographic variables such as age and sex. To ensure robustness and reproducibility, the model was subsequently validated using two independent cohorts: the Geisinger health system cohort in the United States and the FinnGen biobank in Finland. This multi-cohort approach allowed the investigators to test the model across different populations and healthcare systems.
Predictive Power of the Genetic Risk Score Model
The study demonstrated that incorporating a genetic risk score significantly improved the prediction of future MS diagnosis among individuals presenting with optic neuritis. Specifically, each one-standard-deviation increase in the MS genetic risk score was associated with a 1.3-fold increase in the hazard of developing MS. Statistical analysis revealed that this relationship was significant, suggesting that genetic predisposition contributes meaningfully to the risk of disease progression. Importantly, the addition of genetic information enhanced predictive accuracy beyond demographic factors alone, illustrating the value of integrating genomic data into clinical risk models.
Risk Stratification and Clinical Outcomes
A key finding of the study was the ability of the model to stratify patients into distinct risk categories. Participants were divided into quartiles based on their predicted risk scores. The results showed substantial variation in the incidence of multiple sclerosis across these groups: individuals in the lowest-risk quartile had an approximate 4% risk of developing MS, whereas those in the highest-risk quartile exhibited a dramatically higher risk of around 41%. This gradient demonstrates the potential of the model to identify patients at particularly high risk of disease conversion. Such stratification could enable clinicians to tailor monitoring strategies and consider early intervention for high-risk individuals.
Validation Across Independent Cohorts
To ensure that the findings were not limited to a single dataset, the predictive model was tested in two external cohorts. The replication of results in both the Geisinger and FinnGen populations reinforced the reliability and generalizability of the model. Cross-cohort validation is a critical component of translational research because it demonstrates that a predictive framework can be applied across diverse genetic backgrounds and healthcare environments. The successful replication of the model’s predictive performance strengthens the evidence that genetic risk scores can be a meaningful addition to clinical decision-making tools.
Implications for Precision Medicine in Neuroimmunology
The integration of genetic risk scores with clinical data represents an important step toward precision medicine in neuroimmunology. For patients presenting with optic neuritis, early identification of those at high risk of developing multiple sclerosis could guide more proactive monitoring and earlier initiation of disease-modifying therapies. Conversely, patients identified as low risk may avoid unnecessary treatment and anxiety associated with uncertain prognosis. As genomic data become increasingly integrated into healthcare systems, predictive models such as this one may transform the diagnostic and therapeutic landscape for neuroinflammatory diseases.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Rivier, C. A., Payabvash, S., Zhao, H., Hafler, D. A., Falcone, G. J., & Longbrake, E. E. (2024). Differential Results of Polygenic Risk Scoring for Multiple Sclerosis in European and African American Populations. medRxiv, 2024-06.
